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Abstract
APOE ε4, the most significant genetic risk factor for Alzheimer disease (AD), may mask effects of 
other loci. We re-analyzed genome-wide association study (GWAS) data from the International 
Genomics of Alzheimer’s Project (IGAP) Consortium in APOE ε4+ (10,352 cases and 9,207 
controls) and APOE ε4− (7,184 cases and 26,968 controls) subgroups as well as in the total 
sample testing for interaction between a SNP and APOE ε4 status. Suggestive associations 
(P<1x10−4) in stage 1 were evaluated in an independent sample (stage 2) containing 4,203 subjects 
(APOE ε4+: 1,250 cases and 536 controls; APOE ε4-: 718 cases and 1,699 controls). Among 
APOE ε4− subjects, novel genome-wide significant (GWS) association was observed with 17 
SNPs (all between KANSL1 and LRRC37A on chromosome 17 near MAPT) in a meta-analysis of 
the stage 1 and stage 2 datasets (best SNP, rs2732703, P=5·8x10−9). Conditional analysis revealed 
that rs2732703 accounted for association signals in the entire 100 kilobase region that includes 
MAPT. Except for previously identified AD loci showing stronger association in APOE ε4+ 
subjects (CR1 and CLU) or APOE ε4− subjects (MS4A6A/MS4A4A/ MS4A6E), no other SNPs 
were significantly associated with AD in a specific APOE genotype subgroup. In addition, the 
finding in the stage 1 sample that AD risk is significantly influenced by the interaction of APOE 
with rs1595014 in TMEM106B (P=1·6x10−7) is noteworthy because TMEM106B variants have 
previously been associated with risk of frontotemporal dementia. Expression quantitative trait 
locus analysis revealed that rs113986870, one of the GWS SNPs near rs2732703, is significantly 
associated with four KANSL1 probes that target transcription of the first translated exon and an 
untranslated exon in hippocampus (P≤1.3x10−8), frontal cortex (P≤1.3x10−9), and temporal cortex 
(P≤1.2x10−11). Rs113986870 is also strongly associated with a MAPT probe that targets 
transcription of alternatively spliced exon 3 in frontal cortex (P=9.2x10−6) and temporal cortex 
(P=2.6x10−6). Our APOE-stratified GWAS is the first to show GWS association for AD with 
SNPs in the chromosome 17q21.31 region. Replication of this finding in independent samples is 
needed to verify that SNPs in this region have significantly stronger effects on AD risk in persons 
lacking APOE ε4 compared to persons carrying this allele, and if this is found to hold, further 
examination of this region and studies aimed at deciphering the mechanism(s) are warranted.
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INTRODUCTION
The common late-onset form of Alzheimer disease (AD) has a strong genetic component,1 a 
portion of which is explained by APOE and several other genes identified by positional 
mapping, targeted gene analysis and genome-wide association studies (GWAS).2–4 Together, 
these loci account for less than one-half of the heritable component in AD susceptibility, of 
which 20%–25% is due to APOE.4,5 Because many of the known AD loci cluster in 
biological pathways, including those involved in inflammation, lipid metabolism and 
processing, and intracellular trafficking of Aβ, there are likely more AD risk loci that are 
difficult to detect because of very weak effect size, allelic heterogeneity, or rare variants. To 
examine yet another hypothesis, namely, that associations for some loci may be obscured by 
confounding or interaction with other loci, we conducted a two-stage GWAS in APOE 
genotype subgroups using the large resources of the International Genomics of Alzheimer’s 
Project (IGAP).
METHODS
Study Population
Details of the stage 1 sample from the International Genomics of Alzheimer’s Project 
(IGAP) Consortium including subject recruitment, genotyping, imputation, quality control, 
population substructure, and statistical methods for association analyses were previously 
described.4 In brief, phenotype and genotype data, including APOE genotypes, for a total of 
53,711 subjects were assembled by IGAP from the Alzheimer’s Disease Genetic 
Consortium (ADGC), the Cohorts for Heart and Ageing Research in Genomic Epidemiology 
(CHARGE) consortium, the European Alzheimer’s Disease Initiative (EADI), and the 
Genetic and Environmental Risk in Alzheimer’s Disease (GERAD) consortium. 
Characteristics of this sample are in Supplementary Table S1.
The stage 2 dataset included GWAS and APOE genotype data for 4,203 subjects of 
European ancestry from the ADC4, ADC5, ADC6, MTV, Pfizer, and TARCC datasets in the 
ADGC. These individuals were recruited under protocols approved by the appropriate 
Institutional Review Boards. Details of the individual datasets are provided in the 
Supplementary Materials and summarized in Supplementary Table S1.
Procedures
QC, Imputation, and Population Substructure in Stage 2 Datasets—Quality 
control of the clinical and genotype data in these cohorts was performed using procedures 
described elsewhere.4 SNP genotypes in each stage 2 dataset were imputed with IMPUTE2 
using reference haplotypes from the March 2012 release of 1000 Genomes. We compared 
imputation results for selected variants in the stage 1 datasets using the March 2012 release 
of 1000 Genomes and prior imputation on the December 2010 release, and found no 
significant difference in the distribution of genotype probabilities between old and new 
imputations for the same samples among the original ADGC datasets. We used actual APOE 
genotypes when available because previously we observed that imputation in this region 
using the 1000 Genomes reference panel is unreliable.5 Population substructure was 
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evaluated within each dataset by principal components (PC) analysis using EIGENSTRAT 
(http://www.hsph.harvard.edu/alkes-price/software/) and a subset of 21,109 SNPs common 
to all genotyping platforms.
Statistical Analysis
Genome-wide Association Study—Within each stage 1 dataset, genome-wide 
association analyses were conducted separately in subgroups of subjects with and without 
the APOE ε4 allele using a logistic generalized linear model (GLM) in case-control datasets 
and a logistic generalized estimating equation (GEE) in family-based datasets. The potential 
independent effect of the APOE ε2 allele was not examined because of the paucity of 
carriers of this allele, thus rendering very small cell sizes particularly among AD cases and 
in smaller datasets. Cox-proportional hazards models were used to evaluate association with 
incident AD in three CHARGE cohorts. A quantitative estimate between 0 and 2 for the 
dose of the reference allele for a SNP was used to incorporate the uncertainty of the 
imputation estimates. Interaction between a SNP and APOE genotype was evaluated in the 
APOE genotype subgroups combined within each dataset using regression models including 
age, sex, the first three PCs, and terms for the SNP, APOE ε4 status, and interaction between 
the SNP and APOE ε4 status. Results for each model across datasets were combined by 
meta-analysis using the inverse variance method implemented in the software package 
METAL (http://www.sph.umich.edu/csg/abecasis/Metal/). Effect sizes were weighted by 
their inverse variance and a combined estimate was calculated by summing the weighted 
estimates and dividing by the summed weights. SNPs with a minor allele frequency >5% 
that were available in at least 50% of the datasets were included in the meta-analysis. The 
meta-analysis P-value for association was estimated by the summarized test statistic, after 
applying genomic control within each individual study.
Follow-up Analysis in Stage 2 Datasets—SNPs attaining a P-value <10−4 in the stage 
1 GWAS were evaluated in each of the stage 2 GWAS datasets, containing a total of 1,786 
APOE ε4+ and 2,417 APOE ε4− subjects (Supplementary Table S1), using the same 
approach described above.
Gene Expression Analysis
The effect of top-ranked SNPs on gene expression was evaluated using an open access 
database of control brain microarray data (BRAINEAC) made publically available by the 
UK Human Brain Expression Consortium (http://caprica.genetics.kcl.ac.uk/BRAINEAC). 
This dataset contains information generated by analysis of tissue samples obtained from 12 
different central nervous system regions in 134 individuals. Details of the expression 
quantitative trait locus (eQTL) analysis are reported elsewhere.6 In this study, the 
experiment-wise significance threshold for association of a genetic marker with expression 
was determined to be 1.6x10−7 at the gene level and 1.8x10−6 for individual exons. Potential 
for functionality of the top-ranked SNPs was assessed using the Regulome database (http://
www.regulomedb.org).
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RESULTS
We conducted a genome-wide association study for AD using datasets stratified by APOE 
genotype assembled by IGAP which were from the ADGC, CHARGE consortium, EADI, 
and GERAD consortium. Meta-analyses were performed separately in APOE ε4+ (10,246 
cases and 11,924 controls) and APOE ε4− (7,231 cases and 19,603 controls) subgroups, as 
well as the total sample using a model including a term for the interaction of the SNP with 
the APOE ε4 status. There was limited genomic inflation in the GWAS results in the APOE 
ε4+ (λ=1.05) and APOE ε4− (λ=1.06) groups, but not in the total sample (λ=0.98) testing 
the ε4 * SNP interaction (Supplementary Figure S1). Genome-wide significant (GWS) 
association (P<5x10−8) for AD was found in five distinct regions (CR1, BIN1, CLU, 
PICALM and APOE) in the APOE ε4+ subgroup (Supplementary Figure S2A, 
Supplementary Table S2) and four distinct regions (BIN1, HBEGF, MS4A6A/MS4A4A, 
SLC24A4, and APOE) in the APOE ε4− subgroup (Supplementary Figure S2B, 
Supplementary Table S2). No significant SNP*APOE interactions were found in the total 
group (Supplementary Figure S2C). Suggestive association (P<10−6) was observed with 
SNPs in five novel loci in the APOE ε4− subgroup (SOX14/CLDN18, ACSL6, FAM20C, 
MAPT region, and CDR2L; Supplementary Figure S2B, Supplementary Table S3) and with 
21 TMEM106B SNPs (top result: rs1595014, P=1.6x10−7) (Supplementary Figure S2C, 
Supplementary Table S3).
Approximately 1,130 SNPs from 38 regions (including seven previously established AD 
loci) were tested in Stage 2 (Supplementary Table S3). Follow-up analyses of the novel loci 
confirmed association with SNPs in CDC42SE2-ACSL6, KANSL1/LRRC37A, and CDR2L 
in the stage 2 sample (Table 1, Supplementary Table S2), but only SNPs near MAPT and 
between KANSL1 and LRRC37A (Figure 1A) were genome-wide significant after 
combining results from the stage 1 and stage 2 samples (best SNP: rs2732703, meta-
analysis: P=5.8x10−9). The association was consistent in nearly all datasets which contained 
rs2732703 information (Figure 1B). To verify the reliability of the association with 
rs2732703, an imputed SNP, we compared rs2732703 allele dosages obtained directly by 
genotyping using a Taqman assay with those derived from imputation among 1,010 subjects 
from the ACT, ADC4, ADC5 and ADC6 datasets. The correlation of these values, 0.813 in 
the entire sample and 0.834 among APOE ε4− subjects, as well as a genotype 
misclassification rate of only 3.5% among subjects with imputed probability scores > 0.8 for 
a particular genotype, suggest that our association findings were not influenced substantially 
by imputation quality.
Further examination of this region in the total sample revealed an association peak spanning 
more than 1.25 Mb that contains 15 genes (Figure 1A). Within this region, 17 SNPs were 
GWS, have MAFs ranging from 0.13 to 0.17, and are located in a 10.2 kb segment upstream 
of both KANSL1 and LRRC37A (Supplementary Table S4). Nominally significant 
association was observed with only one of these SNPs among ε4+ subjects (rs2732703, 
P=0.02) (Supplementary Table S3). Although the odds ratios (OR) for effect of the effect of 
minor allele on AD risk were substantially lower for all of the GWS SNPs in the ε4− group 
(0.54< OR <0.86) than in the ε4+ group (0.76< β <1.04), there was no evidence of 
interaction with APOE genotype (Supplementary Table S3). The minor alleles of these SNPs 
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reduced AD risk by 20%–37% in the ε4− group. The 350 kb gap in the broad association 
signal is punctuated at one end by a “cliff” adjacent to the MAPT-KANSL1-LRRC37A 
association peak (Figure 1). This gap is populated by relatively few SNPs and contains 
several copy number variation (CNV) polymorphisms.7,8 To explore the possibility that the 
association observed in the present analysis is explained by previously identified haplotypes 
H1/H2 in the MAPT region,8 we evaluated six models in the entire dataset conditioning on 
rs8070723 (an H1/H2 tagging SNP), rs2732703, or rs199533. Rs2732703 remained 
significant in models conditioning on rs8070723 (P=0.013) or rs199533 (P=0.0020), and 
rs8070723 was marginally significant in the model conditioning on rs199533 (P=0.043) 
(Supplementary Table S5, Supplementary Figure S3). These results suggest that KANSL1/
LRRC37A is the only AD risk locus in this region.
We also examined the effect of APOE ε4 status on previously established AD loci 
(Supplementary Table S2). Four of these loci attained genome-wide significance in at least 
one of the APOE subgroups (Table 2), and the association signal in the MS4A cluster region 
was evident primarily in the APOE ε4− subgroup (Supplementary Figure S4). The 
association of AD with CR1, BIN1, and CLU was supported in both APOE subgroups.
Next, we interrogated the BRAINEAC database to determine whether any of the 17 GWS 
SNPs located between KANSL1 and LRRC37A are cis-eQTLs. Data were available for only 
one of these SNPs (rs113986870) which is in high LD with and 2,461 base pairs away from 
rs2732703 (r2 and D′>0.9). Ten exon probes from four genes (KANSL1, LRRC37A4P, 
MAPT, and C17orf69) were significantly associated with rs113986870 when averaged 
across all brain regions (Table 3). Rs113986870 was significantly associated with gene-level 
expression (Figure 2A) as well as with exon-level expression (Figure 2B) in hippocampus, 
temporal cortex, and cerebellum. In these brain regions, rs113986870 was significantly 
associated with KANSL1 probes 3762011, 3762012 and 3762013 that measure expression 
of the first translated exon. Additionally, we observed that expression of probe 3760518 
(Supplementary Figure S5A) present in all three transcripts (NM_001193466, NM_015443, 
and NM_001193465) and 3760219 in transcript variant 2 (NM_015443) was significantly 
associated with rs113986870 (Supplementary Figure S5B), while expression of probe 
3760217 in transcript variant 1 ((NM_001193466) was not significant (Supplementary 
Figure S5C), indicating that alternative splicing may be a crucial mechanism for regulating 
KANSL1 expression. Rs113986870 was also strongly associated with MAPT transcription 
(Supplementary Figure S6A) and in particular with probe 3723712 that targets transcription 
of alternatively spliced exon 3 in frontal cortex (P≤9.2x10−6) and temporal cortex 
(P≤2.6x10−6) (Supplementary Figure S6B). The rs113986870 minor allele (A), which is 
associated with reduced risk of AD (Supplementary Table S4), increased expression of the 
target exons in KANSL1 and MAPT (Figure 2, Supplementary Figure S6, Supplementary 
Figure S7). The association with LRRC37A4P exon probe 3759898 was significant in all 
three AD-related brain regions (P≤3.6x10−9). The association of rs113986870 with exon 
probe 3723594 for C17orf69 was significant in hippocampus only (P=1.6x10−7). Five of the 
GWS SNPs including rs2732703 and rs113986870 are located within a transcription factor 
binding site or a DNase sensitivity peak and two of these five SNPs, including rs2668626 
which is only 47 bp from rs2732703, have also been identified within an eQTL 
(Supplementary Table S4).
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DISCUSSION
This study was undertaken to identify loci whose effect on AD risk may be obscured by 
confounding or interaction with APOE genotype. Our APOE-stratified GWAS is the first to 
show GWS association for AD with SNPs in the chromosome 17q21.31 region including 
MAPT, KANSL1 and LRRC37A. Among the genes expected to emerge from GWAS but 
never seen before is MAPT which encodes the microtubule-associated protein tau (MAPT) 
found in AD neurofibrillary tangles. The association peak is located between KANSL1 and 
LRRC37A, approximately 200 kb downstream of MAPT, in a subset of subjects that do not 
possess the APOE ε4 allele. Although the association signal includes MAPT, conditional 
analysis suggests that the causal variant(s) are more likely located in a DNA segment 
between the 5′ end of KANSL1 and 5′ end of LRRC37A and not within MAPT or another 
gene distal to LRRC37A.
The nature of the AD-related functional variant could not be discerned from our genetic 
association findings. None of the GWS SNPs are within 42.1 kb of the KANSL1 start site or 
16.8 kb of the LRRC37A start site, suggesting that the functional variant is not within the 
promoter region of either gene. KANSL1 is a widely expressed gene encoding a member of 
the nonspecific lethal (NSL) complex. The KANSL1 protein is an evolutionarily conserved 
regulator of the chromatin modifier KAT8, which influences gene expression through 
histone H4 lysine 16 (H4K16) acetylation.9 Notably, mutations in KANSL1 cause the 
17q21.31 microdeletion syndrome which is associated with a wide range of abnormalities 
including intellectual disability and developmental delay, and is therefore thought to be 
involved in neuronal development.10,11 LRRC37A encodes a member of the leucine-rich 
repeat containing 37 family. Leucine-rich repeats (LRRs) are protein-ligand interaction 
motifs found in a large number of proteins with different structure, localization, and 
function.12 LRR motifs are important for intermolecular or intercellular interactions with 
exogenous factors in the immune system and/or with different cell types in the developing 
nervous system.12
However, expression analysis of exon array data in control brain tissue revealed that 
rs113986870, which is in high LD with the top-ranked SNP (rs2732703) in the GWAS, is an 
eQTL for expression of the first translated exon in KANSL1 and the alternatively spliced 
exon 3 in MAPT. Previous studies suggest that splicing of MAPT may be a crucial 
regulatory mechanism in the brain and tauopathies in particular,13 and that increased 
expression of exon 3 protects against neurodegeneration.14 Although rs113986870 is 
apparently not an eQTL for its adjacent gene LRRC37A, it was significantly associated with 
a closely related gene, LRRC37A4P, in all three AD-related brain regions. These results 
suggest that rs113986870 may have a potential function as a cis-acting regulatory element 
for multiple genes in this region. Another confounding feature of this region are copy 
number variations that in part overlap with the 5′ end of KANSL1 and possibly influence 
expression.7,8 Thus, it is possible that the exon probes targeting the first translated in 
KANSL1 may be tagging this duplication. In addition, interrogation of a database curating 
information about DNA features and regulatory regions revealed that five of the GWS SNPs, 
including rs2732703 and rs113986870, may have strong regulatory potential.
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The association peak for AD on chromosome 17q21.31 is located in a well-recognized and 
perplexing genomic region containing a 900 kb inversion.8 Previous GWAS identified 
associations of variants within and at the edges of this inversion with Parkinson disease 
(PD)15 and progressive supranuclear palsy (PSP),16 but the most significant associations 
were not with SNPs between KANSL1 and LRRC37A (Supplementary Table S6). Multiple 
studies have identified more than 40 MAPT deletions, missense mutations, and splice site 
mutations that cause frontotemporal dementia (FTD).17 Although AD is only nominally 
associated with common variants in MAPT, previously we observed association of a rare 
MAPT variant (A152T) with increased risk for FTD and AD in a large sample,18 a finding 
which was supported by a subsequent smaller study.19 Ikram et al identified a GWS 
association peak with a KANSL1 SNP approximately 166 kb away from our most 
significant AD SNP (rs2732703) for a continuous measure of intracranial volume in a 
sample of nearly 10,000 community-dwelling elders (Supplementary Table S6).20 These two 
SNPs are moderately correlated (r2=0.71) which indicates that they may tag the same 
functional variant.
Other studies have focused on two divergent extended MAPT haplotypes, H1 and H2, which 
are in near complete LD with status of the inversion and contain independently derived 
partial duplications of KANSL1.8,16 The common H1 haplotype is associated with increased 
risk of FTD,21 PD,22 PSP,23 and corticobasal degeneration (CBD),23 while H2 is linked to 
recurrent deletion events associated with the 17q21.31 microdeletion syndrome.10 Among 
these non-AD forms of dementia, it is possible for FTD to masquerade clinically as AD and 
thereby cases of FTD could be present in our study group; however, any inadvertent 
inclusion of FTD cases is expected to be very small since the minimum age of dementia 
onset in our study group was 60 years and onset of dementia from FTD after age 69 years is 
relatively rare compared to AD that in most cases occurs after age 69.24 Furthermore, a 
recent review of almost 5000 autopsy brains from a subset of cases in the ADGC cohort 
failed to identify any case of FTD.25 Myers et al. reported association of AD with H1 and 
with common MAPT SNPs,26 but this association is controversial27 and did not reach 
genomewide significance in our study or previous GWAS. Another recent study showed that 
carriers of at least one H2 allele had a 5.4-fold increased risk of worsening hallucinations, 
but this result was marginally significant.28 Previously, we observed in a subset of the 
sample studied here that the H2-haplotype tagging rs8070723-G allele was associated with 
reduced risk of AD.29 However, this variant is no longer associated after conditioning on 
rs2732703 (Supplementary Table S5). In carriers of H2, the ancestral haplotype in both 
humans and chimpanzees,30 increased expression of exon 3 in MAPT has been associated 
with an eQTL located approximately 1,500 bp from rs113986870 which decreases 
aggregation of microtubules.31,32 These observations are consistent with our results showing 
that the rs113986870 minor allele is protective for AD and associated with elevated exon3 
expression.
There is a large body of experimental evidence linking tau protein to AD pathogenesis,33 
and some studies show evidence of association of AD with common MAPT SNPs.29,34 
However, analysis of the MAPT coding sequence did not reveal disease-causing variants for 
early-onset AD 35 and other studies examining association of MAPT SNPs with late-onset 
AD were negative.27,36 Recently, Allen et al. reported that the rs8070723-G allele was 
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associated with reduced MAPT expression in the cerebellum and temporal cortex of AD 
subjects.29 Robust genetic associations have also been identified for AD with several genes 
in cytoskeletal and axonal transport pathways including tau or leading to neurofibrillary 
tangles, most notably BIN1, EPHA1, RIN3, CASS4, and FERMT2.4
Based on the observation that overexpression of human ApoE4 in transgenic mouse neurons 
results in hyperphosphorylation of tau,37 it is possible that associations with AD-related loci 
in the chromosome 17q21.31 region are obscured by the much stronger effect of APOE ε4 
on MAPT expression or function.38 This idea is consistent with lack of GWS association 
with 17q21.31 SNPs in the same dataset without stratification by APOE genotype,4 and no 
evidence for interaction between APOE and any SNPs in the MAPT-KANSL1-LRRC37A 
region in the current study. Another possible explanation for the significant association of 
17q21.31 SNPs with AD only among subjects lacking APOE ε4 is genetic heterogeneity 
suggesting that variation at the chromosome 17q21.31 locus is associated with a distinct 
etiological subtype of AD where tau is the primary disease activator.39 Finally, the diagnosis 
of AD for most subjects in this dataset was established clinically suggesting the possibility 
of misdiagnosis or AD accompanied by other processes associated with other dementing 
illnesses. Further studies are needed to determine whether this subtype can be distinguished 
clinically or neuropathologically.
Our study also showed that the previously established association with the MS4A gene 
cluster is derived almost completely from subjects lacking APOE ε4, suggesting the 
contribution of the MS4A locus to AD may be mechanistically different than AD-related 
processes that are associated with APOE ε4. Members of the MS4A gene family encode 
membrane proteins, some of which have known roles in immune cell function,40 however, 
little is known about the function of MS4A6A, MS4A4A or MS4A6E in humans. Karch et 
al. showed that expression of MS4A6A was upregulated in AD brains of AD patients 
compared to brains of controls, and significantly correlated with AD status, AIF1 expression 
(a marker for microglia which is the immune cell of the brain), cognitive dementia rating 
score, and extent of AD neuropathologic change.41
The observed statistical interaction of genotypes for TMEM106B with APOE on AD risk in 
the stage 1 GWAS is noteworthy (rs1595014, P=1.6x10−7) even though it is not supported 
by results in the comparatively small stage 2 sample. TMEM106B is a glycoprotein 
predominantly localized at the lysosomal membrane where it might interact with 
intracellular progranulin (GRN).42,43 TMEM106B variants, particularly the p. T185S 
(rs3173615) mutation, are risk factors for FTD, especially among persons carrying a GRN 
mutation.44 TMEM106B variants are also associated with development of cognitive 
impairment in amyotrophic lateral sclerosis45 and implicated in the pathologic presentation 
of AD.46 Cruchaga et al observed association of the TMEM106B SNP rs1990622 risk allele 
with younger onset of the FTLD subtype with TAR DNA-binding protein inclusions (FTLD-
TDP),47 a pattern reminiscent of the association of APOE ε4 with increased risk and 
younger onset of AD. The biological underpinning of the interaction of TMEM106B with 
APOE affecting AD risk is unclear.
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Our top findings, including those that are genome-wide significant, should be confirmed in 
independent samples. Functional studies will be needed to understand the relationship 
between APOE and the causative variant(s) in 17q21.31 once they are identified, as well as 
with other loci showing much stronger association with AD in particular APOE genotype 
strata (e.g., MS4A6A/MS4A4A/ MS4A6E) or through interaction with APOE (e.g., 
TMEM106B). Our study provides a firm genetic connection of AD to several other 
pathologically distinct disorders in which dementia is a cardinal or common characteristic.
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Figure 1. 
Association of AD with SNPs in chromosome 17q21.31 in the combined stage 1 and stage 2 
samples. (A) Regional Manhattan plot in the APOE ε4+ (upper panel) and the APOE ε4− 
(lower panel) subgroups. SNPs with the lowest P-value are indicated with a purple diamond. 
Computed estimates of linkage disequilibrium (r2) of SNPs in this region with the most 
significant SNP are shown as red circles for r2 ≥ 0.8, orange circles for 0.6 ≤ r2 < 0.8, green 
circles for 0.4 ≤ r2 < 0.6, light blue circles for 0.2 ≤ r2 < 0.4, and blue circles for r2 < 0.2. 
Unannotated SNPs are shown as grey circles. (B) Forest plot of association results for 
rs2732703 in the Stage 1, Stage 2 and total samples among APOE ε4− subjects.
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Figure 2. 
Genotype specific effect of the eQTL rs113986870 on expression of KANSL1. (A) Gene-
level expression of KANSL1 transcript t3760137. Transcript-level expression represents the 
average across all KANSL1 exon probe sets. (B) Expression of exon probe 3760212. Probes 
3760211, 3760212, and 3760213 measure expression of the first translated exon, are present 
in all three transcript variants, and were significantly associated with the eQTL. Expression 
profiles for probes 3760211 and 3760213 showed similar to those for probe 3760212 (Table 
3). The distance from 3760212 to rs113986870 is 85,431 base pairs. Log2 scale of 
expression (Y-axis) is shown for 10 regions of cognitively normal human brains (X-axis) 
ordered by mean expression level. Rs113986870 genotype counts: AA=0, AG=56, and 
GG=76. Rs113986870 allele frequencies are 0.21 (A) and 0.79 (G). CRBL = cerebellum, 
FCTX = frontal cortex, HIPP = hippocampus, MEDU = medulla (specifically inferior 
olivary nucleus), OCTX = occipital cortex (specifically primary visual cortex), PUTM = 
putamen, SNIG = substantia nigra (SNIG), THAL = thalamus, TCTX = temporal cortex), 
WHMT = intralobular white matter.
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